SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after its Q4 earnings report, which largely surpassed estimates, yet the stock saw a significant decline. Community discussion is polarized, with bulls viewing the dip as an oversold opportunity, highlighting strong subscriber growth and accelerating ad revenue. Conversely, bears are focused on cautious forward guidance, increased content spending, and the pause in share buybacks tied to a potential major acquisition, fueling concerns about near-term shareholder value.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is surging to new all-time highs, propelled by escalating geopolitical tensions stemming from recent tariff threats against European nations and discussions around Greenland. The community views this as a significant risk-off catalyst, driving substantial safe-haven inflows amid broader concerns over global stability and the dollar's future. While many anticipate further gains, calls for caution and potential profit-taking are also emerging as the metal's ascent becomes parabolic.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to multiple analyst upgrades and recent news of a significant U.S. SHIELD defense contract for chip supply, which the community views as a major catalyst. Investors are actively discussing the upcoming earnings, robust demand for server CPUs driven by AI, and the stock's notable resilience amidst broader market volatility, with many anticipating a move past key resistance levels.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of a potential acquisition by Zydus Lifesciences, sparking community speculation about a bidding war for the undervalued biotech. This is amplified by recent strong preliminary financial results, accelerated IBSRELA revenue guidance to $1 billion by 2029, and a pivotal patent extension to 2041 for both its key therapies. These developments firmly position Ardelyx as a compelling long-duration asset and an attractive target in the current biotech market landscape.

America's Oil Reserve for the Digital Age

U.S Oil

USOR Crypto is trending amidst extreme volatility, with community members fiercely debating its legitimacy as a Solana meme coin following a rapid price surge. While some anticipate significant further gains leading up to a key February 1st date, others are cautioning against a potential "rug pull" scenario, with many also discussing its inconsistent availability on various exchanges.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is currently trending following news of a significant public offering and a strategic private placement to Medtronic, exciting investors about potential validation and future prospects. The community is actively discussing the implications of this institutional investment and the concurrent start of its pivotal PARADIGM trial for the DurAVR heart valve, balancing optimism with concerns over share dilution.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst significant market uncertainty driven by former President Trump's recent geopolitical rhetoric concerning Greenland and tariffs, coupled with anticipation of his upcoming Davos speech. This has spurred intense community debate, with some advocating to "buy the dip" while others voice concerns over a potential market downturn, especially as gold prices reach new all-time highs.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF ($GDX) is trending higher as gold and silver surge to fresh record highs, fueled by escalating geopolitical tensions, renewed tariff threats, and global monetary policy that signals persistent currency debasement. The community is actively discussing expectations of aggressive liquidity injections and central bank gold accumulation, leading many to believe miners are poised for significant upside due to expanding margins and a perceived catch-up trade relative to the underlying commodities.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending due to significantly raised revenue guidance for 2026 and its strategic expansion into the space domain with a new contract win. The community is actively discussing the company's potential as a defense, AI, and robotics player, with many anticipating future government contracts and a possible short squeeze, despite some past volatility.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing extreme volatility and a significant decline, as natural gas prices surge on forecasts predicting colder U.S. weather and heightened heating demand, triggering a notable short squeeze. The community is actively discussing KOLD's dramatic daily drops and the rapid ascent of its inverse, highlighting the "widowmaker" nature of natural gas markets as traders navigate this weather-driven rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Research Issues Pessimistic Forecast for PBYI Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research decreased their Q1 2027 earnings estimates for Puma Biotechnology in a research report issued to clients...

Ritholtz Wealth Management Raises Stake in Puma Biotechnology, Inc. $PBYI

Ritholtz Wealth Management lifted its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 139.0% during the third quarter, according to its most recent disclosure with the Securities...

Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above 200 Day Moving Average - What's Next?

Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average - What's Next...

Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving Average - Here's What Happened

Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average - Time to Sell...

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday...

CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?

CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.

Acorn Capital Advisors LLC Has $14.17 Million Stake in Puma Biotechnology, Inc. $PBYI

Acorn Capital Advisors LLC grew its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 4.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange...

American Century Companies Inc. Grows Stake in Puma Biotechnology, Inc. $PBYI

American Century Companies Inc. grew its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 16.8% in the 2nd quarter, according to the company in its most recent 13F filing...

Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Time to Sell...

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.19	--	--	N/A
Q3 '25	$0.05	$0.17	277.78%	BEAT
Q2 '25	$0.09	$0.12	41.18%	BEAT
Q1 '25	-$0.02	$0.06	400.00%	BEAT
Q4 '24	$0.09	$0.39	350.00%	BEAT

PBYI
Puma Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest PBYI News

PBYIPuma Biotechnology Inc